Clinical Trial Update: Efficacy, Immunogenicity and Safety Study of GSKs Recombinant Zoster Vaccine Shingrix (GSK1437173A) in Chinese Adults Aged ≥50 Years [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating efficacy, immunogenicity, and safety of Shingrix in Chinese adults aged 50 and older; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Herpes Zoster

Drugs mentioned

• Shingrix (recombinant zoster vaccine, adjuvanted)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Herpes Zoster | Phase 4 | Status: COMPLETED | Results posted: 2024-09-19